GE’s SPECT System Gets FDA Clearance
GE Healthcare’s advanced single head nuclear medicine gamma camera with SPECT capability has received FDA clearance.
GE Healthcare’s advanced single head nuclear medicine gamma camera with SPECT capability has received FDA clearance, the company announced.
The Brivo NM615, designed as a cost-effective way to perform routine scanning while expanding their capabilities, allows doctors to lower injected patient dose by up to 50 percent of those of standard nuclear medicine scanning protocols, or the potential for patients to spend less time on the exam table, without compromising image quality, according to the company.
The system has a 70 cm wide bore and table capable of handling patients up to 500 pounds. The Brivo NM 615 can also be upgraded on site to the GE Healthcare Discover NM630 or the Discovery NM/CT 670 SPECT/CT hybrid systems. As a result, the system may expand the capability to serve patients in the future at faster speeds and with SPECT/CT hybrid scans.
Brivo NM615 can be used with the advanced Xeleris workstation, which integrates new and existing nuclear medicine equipment, including legacy GE and non-GE devices.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
